Compare

CDP-Choline vs RU-58841

Side-by-side observational reports from PeptIQ users. This compares self-reported patterns — not clinical head-to-head trials.

Last reviewed . By the PeptIQ team.

Observational reporting only — not medical advice. Does not recommend doses, protocols, or treatments.

CDP-Choline

208 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 52% · Mixed 36% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Mood
159
Focus
52
Sleep quality
152
Lean mass
119
Joint comfort
115

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Fatigue
75
Nausea
132
Water retention
117
Appetite loss
115
Injection site reaction
114

Self-reported dose per injection

Median bucket: 0.2–0.4 mg · Most common: 0.1–0.2 mg

Reports span 0.01–2 mg

0.01–0.025 mg
8
0.025–0.05 mg
17
0.05–0.1 mg
25
0.1–0.2 mg
28
0.2–0.4 mg
19
0.4–0.6 mg
11
0.6–1 mg
8
1–2 mg
3

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing12stacking25side effects18cdp-choline16

How repeat users are trending

Among repeat reporters, 62% said they felt similar to their last entry, 32% more positive, and 12% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 15 days · Based on 46 repeat reporters

RU-58841

376 community reports

Overall experience

From check-in ratings — separate from side effects logged below. Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Favorable 70% · Mixed 18% · Unfavorable overall 12%

Most reported benefits

Benefits users selected when logging a favorable or mixed check-in.

Joint comfort
-29
Recovery
-39
Digestive comfort
-40
Skin appearance
-107
Appetite control
-138

Most logged side effects

Side effects are logged separately from overall experience. A favorable check-in can still include nausea, fatigue, or injection-site reactions.

Injection site reaction
-113
Anxiety
-139
Flushing
-75
Headache
-112
GI discomfort
-139

Self-reported dose per injection

Median bucket: 100–200 mcg · Most common: 100–200 mcg

Reports span 10–1000 mcg

10–25
3
25–50
5
50–100
10
100–200
20
200–400
15
400–600
9
600–1000
2

Anonymized self-reports from PeptIQ users — not prescribing guidance. Buckets group similar logged amounts; open-ended top buckets mean “at least” that dose.

Common discussion topics

timing20stacking13side effects36ru-588419

How repeat users are trending

Among repeat reporters, 65% said they felt similar to their last entry, 32% more positive, and 20% more negative.

Overall, repeat reporters leaned more positive than their previous entry.

Median gap between entries: 24 days · Based on 83 repeat reporters

Sources (7)

Published sources linked on the CDP-Choline and RU-58841 wiki pages.

  1. PubMed

    Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial)

    Davalos A, Alvarez-Sabin J, Castillo J, et al. Lancet. 2012

    Source
    Wiki study page →
  2. PubMed

    Effect of citicoline on functional and cognitive status among patients with traumatic brain injury: Citicoline Brain Injury Treatment Trial (COBRIT)

    Zafonte RD, Bagiella E, Ansel BM, et al. JAMA. 2012

    Source
    Wiki study page →
  3. ClinicalTrials.gov

    International Citicoline Trial on Acute Stroke (ICTUS) (NCT00331890)

    ClinicalTrials.gov. Clinical trial registry. 2006

    Source
    Wiki study page →
  4. ClinicalTrials.gov

    Citicoline Brain Injury Treatment Trial (COBRIT) (NCT00545662)

    ClinicalTrials.gov. Clinical trial registry. 2007

    Source
    Wiki study page →
  5. PubMed

    RU 58841, a new specific topical antiandrogen: a candidate for the treatment of androgenetic alopecia

    Miyamoto H, Yeh S, Lardy H, et al. J Steroid Biochem Mol Biol. 1997

    Source
    Wiki study page →
  6. PubMed

    Evaluation of RU58841 as an anti-androgen in prostate PC3 cells and a topical anti-alopecia agent in the bald scalp of stumptailed macaques

    Pan HJ, Wilding G, Uno H, et al. Endocrine. 1998

    Source
    Wiki study page →
  7. PubMed

    Effects of topical antiandrogen and 5-alpha-reductase inhibitors on sebaceous glands in male fuzzy rats

    Ye F, Imamura K, Imanishi N, et al. Skin pharmacology : the official journal of the Skin Pharmacology Society. 1997

    Source
    Wiki study page →